This website is intended for US audiences only.
GL, or generalized lipodystrophy, is a rare and serious disease.
Generalized lipodystrophy (GL) is a serious, progressive, metabolic disease.1,2
GL is characterized by the widespread, permanent lack or loss of adipose tissue, resulting in deficiency of the hormone leptin. As a result, patients may experience severe metabolic abnormalities including insulin resistance, diabetes mellitus, and/or hypertriglyceridemia.
These comorbidities may put patients with GL at risk for life-threatening complications such as liver failure, renal failure, pancreatitis, and heart failure.1,2
GL is complex, heterogenous disease that can be easy to miss.2
1. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy—an AACE consensus statement. EndocrPract. 2013;19(1):107-116.doi:10.4158/endp.19.1.v767575m65p5mr06. 2. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline.J Clin Endocrinol Metab. 2016;101(12):4500-4511. doi:10.1210/jc.2016-2466.